Skip to main content
PMC home page
Philosophical Transactions of the Royal Society B: Biological Sciences logoLink to Philosophical Transactions of the Royal Society B: Biological Sciences
. 2003 May 29;358(1433):905–914. doi: 10.1098/rstb.2003.1273

Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention.

Johannes M Aerts 1, Carla Hollak 1, Rolf Boot 1, Ans Groener 1
PMCID: PMC1693181  PMID: 12803924

Abstract

The physiological importance of the degradative processes in lysosomes is revealed by the existence of at least 40 distinct inherited diseases, the so-called lysosomal storage disorders. Most of these diseases are caused by a deficiency in a single lysosomal enzyme, or essential cofactor, and result in the lysosomal accumulation of one, or sometimes several, natural compounds. The most prevalent subgroup of the lysosomal storage disorders is formed by the sphingolipidoses, inherited disorders that are characterized by excessive accumulation of one or multiple (glyco)sphingolipids. The biology of glycosphingolipids has been extensively discussed in other contributions during this symposium. This review will therefore focus in depth on (type 1) Gaucher disease, a prototypical glycosphingolipidosis. The elucidation of the primary genetic defect, being a deficiency in the lysosomal glucocerebrosidase, is described. Characterization of glucocerebrosidase at protein and gene level has subsequently opened avenues for therapeutic intervention. The development of successful enzyme replacement therapy for type 1 Gaucher disease is discussed. Attention is also paid to the alternative approach of substrate modulation using orally administered inhibitors of glucosylceramide synthesis. Novel developments about the monitoring of age of onset, progression and correction of disease are described. The remaining challenges about pathophysiology of glycosphingolipidoses are discussed in view of further improvements in therapy for these debilitating disorders.

Full Text

The Full Text of this article is available as a PDF (282.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe A., Gregory S., Lee L., Killen P. D., Brady R. O., Kulkarni A., Shayman J. A. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest. 2000 Jun;105(11):1563–1571. doi: 10.1172/JCI9711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aerts J. M., Donker-Koopman W. E., Murray G. J., Barranger J. A., Tager J. M., Schram A. W. A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies. Anal Biochem. 1986 May 1;154(2):655–663. doi: 10.1016/0003-2697(86)90043-6. [DOI] [PubMed] [Google Scholar]
  3. Aerts J. M., Hollak C. E. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol. 1997 Dec;10(4):691–709. doi: 10.1016/s0950-3536(97)80034-0. [DOI] [PubMed] [Google Scholar]
  4. Aerts J. M., Schram A. W., Strijland A., van Weely S., Jonsson L. M., Tager J. M., Sorrell S. H., Ginns E. I., Barranger J. A., Murray G. J. Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochim Biophys Acta. 1988 Mar 17;964(3):303–308. doi: 10.1016/0304-4165(88)90030-x. [DOI] [PubMed] [Google Scholar]
  5. Aerts J. M., Van Weely S., Boot R., Hollak C. E., Tager J. M. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. J Inherit Metab Dis. 1993;16(2):288–291. doi: 10.1007/BF00710267. [DOI] [PubMed] [Google Scholar]
  6. Andersson U., Butters T. D., Dwek R. A., Platt F. M. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol. 2000 Apr 1;59(7):821–829. doi: 10.1016/s0006-2952(99)00384-6. [DOI] [PubMed] [Google Scholar]
  7. Ashwell G., Morell A. G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 1974;41(0):99–128. doi: 10.1002/9780470122860.ch3. [DOI] [PubMed] [Google Scholar]
  8. Barranger J. A., O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis. 2001;24 (Suppl 2):89–88. doi: 10.1023/a:1012440428282. [DOI] [PubMed] [Google Scholar]
  9. Barton N. W., Brady R. O., Dambrosia J. M., Di Bisceglie A. M., Doppelt S. H., Hill S. C., Mankin H. J., Murray G. J., Parker R. I., Argoff C. E. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991 May 23;324(21):1464–1470. doi: 10.1056/NEJM199105233242104. [DOI] [PubMed] [Google Scholar]
  10. Bijsterbosch M. K., Donker W., van de Bilt H., van Weely S., van Berkel T. J., Aerts J. M. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem. 1996 Apr 15;237(2):344–349. doi: 10.1111/j.1432-1033.1996.00344.x. [DOI] [PubMed] [Google Scholar]
  11. Blom Daniël, Speijer Dave, Linthorst Gabor E., Donker-Koopman Wilma G., Strijland Anneke, Aerts Johannes M. F. G. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet. 2002 Dec 6;72(1):23–31. doi: 10.1086/345309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brady R. O. Gaucher's disease: past, present and future. Baillieres Clin Haematol. 1997 Dec;10(4):621–634. doi: 10.1016/s0950-3536(97)80031-5. [DOI] [PubMed] [Google Scholar]
  13. Brady R. O., Kanfer J. N., Bradley R. M., Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest. 1966 Jul;45(7):1112–1115. doi: 10.1172/JCI105417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Brady Roscoe O. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):915–919. doi: 10.1098/rstb.2003.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Butters Terry D., Mellor Howard R., Narita Keishi, Dwek Raymond A., Platt Frances M. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):927–945. doi: 10.1098/rstb.2003.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cox T. M. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis. 2001;24 (Suppl 2):106–88. doi: 10.1023/a:1012496514170. [DOI] [PubMed] [Google Scholar]
  17. Cox T. M., Schofield J. P. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol. 1997 Dec;10(4):657–689. doi: 10.1016/s0950-3536(97)80033-9. [DOI] [PubMed] [Google Scholar]
  18. DE DUVE C., PRESSMAN B. C., GIANETTO R., WATTIAUX R., APPELMANS F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J. 1955 Aug;60(4):604–617. doi: 10.1042/bj0600604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Dice J. F., Terlecky S. R., Chiang H. L., Olson T. S., Isenman L. D., Short-Russell S. R., Freundlieb S., Terlecky L. J. A selective pathway for degradation of cytosolic proteins by lysosomes. Semin Cell Biol. 1990 Dec;1(6):449–455. [PubMed] [Google Scholar]
  20. Erikson A. Remaining problems in the management of patients with Gaucher disease. J Inherit Metab Dis. 2001;24 (Suppl 2):122–88. doi: 10.1023/a:1012452715079. [DOI] [PubMed] [Google Scholar]
  21. Furbish F. S., Steer C. J., Krett N. L., Barranger J. A. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta. 1981 Apr 3;673(4):425–434. doi: 10.1016/0304-4165(81)90474-8. [DOI] [PubMed] [Google Scholar]
  22. Gieselmann Volkmar, Matzner Ulrich, Klein Diana, Mansson Jan Eric, D'Hooge Rudi, DeDeyn Peter D., Lüllmann Rauch Renate, Hartmann Dieter, Harzer Klaus. Gene therapy: prospects for glycolipid storage diseases. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):921–925. doi: 10.1098/rstb.2003.1277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Grabowski G. A., Barton N. W., Pastores G., Dambrosia J. M., Banerjee T. K., McKee M. A., Parker C., Schiffmann R., Hill S. C., Brady R. O. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995 Jan 1;122(1):33–39. doi: 10.7326/0003-4819-122-1-199501010-00005. [DOI] [PubMed] [Google Scholar]
  24. Heitner Rene, Elstein Deborah, Aerts Johannes, Weely Sonja van, Zimran Ari. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis. 2002 Mar-Apr;28(2):127–133. doi: 10.1006/bcmd.2002.0497. [DOI] [PubMed] [Google Scholar]
  25. Helenius A. How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Mol Biol Cell. 1994 Mar;5(3):253–265. doi: 10.1091/mbc.5.3.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hollak C. E., Aerts J. M., Goudsmit R., Phoa S. S., Ek M., van Weely S., von dem Borne A. E., van Oers M. H. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet. 1995 Jun 10;345(8963):1474–1478. doi: 10.1016/s0140-6736(95)91037-9. [DOI] [PubMed] [Google Scholar]
  27. Hollak C. E., Maas M., Aerts J. M. Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis. 2001;24 (Suppl 2):97–88. doi: 10.1023/a:1012492429191. [DOI] [PubMed] [Google Scholar]
  28. Hollak C. E., van Weely S., van Oers M. H., Aerts J. M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994 Mar;93(3):1288–1292. doi: 10.1172/JCI117084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hollak C., Maas M., Akkerman E., den Heeten A., Aerts H. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis. 2001 Nov-Dec;27(6):1005–1012. doi: 10.1006/bcmd.2001.0474. [DOI] [PubMed] [Google Scholar]
  30. Jeyakumar M., Butters T. D., Cortina-Borja M., Hunnam V., Proia R. L., Perry V. H., Dwek R. A., Platt F. M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6388–6393. doi: 10.1073/pnas.96.11.6388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Jonsson L. M., Murray G. J., Sorrell S. H., Strijland A., Aerts J. F., Ginns E. I., Barranger J. A., Tager J. M., Schram A. W. Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur J Biochem. 1987 Apr 1;164(1):171–179. doi: 10.1111/j.1432-1033.1987.tb11008.x. [DOI] [PubMed] [Google Scholar]
  32. Kornfeld S., Mellman I. The biogenesis of lysosomes. Annu Rev Cell Biol. 1989;5:483–525. doi: 10.1146/annurev.cb.05.110189.002411. [DOI] [PubMed] [Google Scholar]
  33. Linehan S. A., Martínez-Pomares L., Stahl P. D., Gordon S. Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med. 1999 Jun 21;189(12):1961–1972. doi: 10.1084/jem.189.12.1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Meikle P. J., Hopwood J. J., Clague A. E., Carey W. F. Prevalence of lysosomal storage disorders. JAMA. 1999 Jan 20;281(3):249–254. doi: 10.1001/jama.281.3.249. [DOI] [PubMed] [Google Scholar]
  35. Mistry P. K., Wraight E. P., Cox T. M. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet. 1996 Dec 7;348(9041):1555–1559. doi: 10.1016/S0140-6736(96)04451-0. [DOI] [PubMed] [Google Scholar]
  36. Moran M. T., Schofield J. P., Hayman A. R., Shi G. P., Young E., Cox T. M. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood. 2000 Sep 1;96(5):1969–1978. [PubMed] [Google Scholar]
  37. Murray G. J., Youle R. J., Gandy S. E., Zirzow G. C., Barranger J. A. Purification of beta-glucocerebrosidase by preparative-scale high-performance liquid chromatography: the use of ethylene glycol-containing buffers for chromatography of hydrophobic glycoprotein enzymes. Anal Biochem. 1985 Jun;147(2):301–310. doi: 10.1016/0003-2697(85)90276-3. [DOI] [PubMed] [Google Scholar]
  38. Neufeld E. F. Lysosomal storage diseases. Annu Rev Biochem. 1991;60:257–280. doi: 10.1146/annurev.bi.60.070191.001353. [DOI] [PubMed] [Google Scholar]
  39. Owada M., Neufeld E. F. Is there a mechanism for introducing acid hydrolases into liver lysosomes that is independent of mannose 6-phosphate recognition? Evidence from I-cell disease. Biochem Biophys Res Commun. 1982 Apr 14;105(3):814–820. doi: 10.1016/0006-291x(82)91042-7. [DOI] [PubMed] [Google Scholar]
  40. Peltonen L. Molecular background of the Finnish disease heritage. Ann Med. 1997 Dec;29(6):553–556. doi: 10.3109/07853899709007481. [DOI] [PubMed] [Google Scholar]
  41. Peters C., von Figura K. Biogenesis of lysosomal membranes. FEBS Lett. 1994 Jun 6;346(1):108–114. doi: 10.1016/0014-5793(94)00499-4. [DOI] [PubMed] [Google Scholar]
  42. Platt F. M., Neises G. R., Dwek R. A., Butters T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994 Mar 18;269(11):8362–8365. [PubMed] [Google Scholar]
  43. Platt Frances M., Jeyakumar Mylvaganam, Andersson Ulrika, Heare Tanya, Dwek Raymond A., Butters Terry D. Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):947–954. doi: 10.1098/rstb.2003.1279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Poorthuis B. J., Wevers R. A., Kleijer W. J., Groener J. E., de Jong J. G., van Weely S., Niezen-Koning K. E., van Diggelen O. P. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999 Jul-Aug;105(1-2):151–156. doi: 10.1007/s004399900075. [DOI] [PubMed] [Google Scholar]
  45. Radin N. S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J. 1996 Apr;13(2):153–157. doi: 10.1007/BF00731489. [DOI] [PubMed] [Google Scholar]
  46. Renkema G. H., Boot R. G., Muijsers A. O., Donker-Koopman W. E., Aerts J. M. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem. 1995 Feb 3;270(5):2198–2202. doi: 10.1074/jbc.270.5.2198. [DOI] [PubMed] [Google Scholar]
  47. Renkema G. H., Boot R. G., Strijland A., Donker-Koopman W. E., van den Berg M., Muijsers A. O., Aerts J. M. Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. Eur J Biochem. 1997 Mar 1;244(2):279–285. doi: 10.1111/j.1432-1033.1997.00279.x. [DOI] [PubMed] [Google Scholar]
  48. Richter J., Karlsson S. Clinical gene therapy in hematology: past and future. Int J Hematol. 2001 Feb;73(2):162–169. doi: 10.1007/BF02981933. [DOI] [PubMed] [Google Scholar]
  49. Rijnboutt S., Aerts H. M., Geuze H. J., Tager J. M., Strous G. J. Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. J Biol Chem. 1991 Mar 15;266(8):4862–4868. [PubMed] [Google Scholar]
  50. Ringdén O., Groth C. G., Erikson A., Granqvist S., Månsson J. E., Sparrelid E. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation. 1995 Mar 27;59(6):864–870. [PubMed] [Google Scholar]
  51. Sandhoff Konrad, Kolter Thomas. Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):847–861. doi: 10.1098/rstb.2003.1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Stahl P. D., Rodman J. S., Miller M. J., Schlesinger P. H. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci U S A. 1978 Mar;75(3):1399–1403. doi: 10.1073/pnas.75.3.1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Van Weely S., Aerts J. M., Van Leeuwen M. B., Heikoop J. C., Donker-Koopman W. E., Barranger J. A., Tager J. M., Schram A. W. Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. Eur J Biochem. 1990 Aug 17;191(3):669–677. doi: 10.1111/j.1432-1033.1990.tb19173.x. [DOI] [PubMed] [Google Scholar]
  54. Vellodi A., Bembi B., de Villemeur T. B., Collin-Histed T., Erikson A., Mengel E., Rolfs A., Tylki-Szymanska A., Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis. 2001 Jun;24(3):319–327. doi: 10.1023/a:1010514614570. [DOI] [PubMed] [Google Scholar]
  55. van Weely S., Brandsma M., Strijland A., Tager J. M., Aerts J. M. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim Biophys Acta. 1993 Mar 24;1181(1):55–62. doi: 10.1016/0925-4439(93)90090-n. [DOI] [PubMed] [Google Scholar]
  56. van Weely S., van den Berg M., Barranger J. A., Sa Miranda M. C., Tager J. M., Aerts J. M. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J Clin Invest. 1993 Mar;91(3):1167–1175. doi: 10.1172/JCI116276. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Philosophical Transactions of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

RESOURCES